Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 9/20 | 0.68 |
| ▸ | CRBN | Q96SW2 | 9/20 | 0.68 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20595430 | 0.95 | DDB1 (0.74) | DDB1CRBNGPR119ALDH1A1 | |
| SCHEMBL20595405 | 0.95 | DDB1 (0.74) | DDB1CRBNGPR119ALDH1A1 | |
| SCHEMBL30120110 | 0.95 | DDB1 (0.74) | DDB1CRBNGPR119ALDH1A1 | |
| SCHEMBL25845750 | 0.93 | DDB1 (0.65) | DDB1CRBNGPR119ALDH1A1 | |
| SCHEMBL23783213 | 0.92 | DDB1 (0.67) | DDB1CRBNGPR119 | |
| SCHEMBL30817363 | 0.91 | DDB1 (0.69) | DDB1CRBNGPR119ALDH1A1 | |
| SCHEMBL31323735 | 0.90 | DDB1 (0.66) | DDB1CRBNGPR119 | |
| SCHEMBL30981069 | 0.90 | DDB1 (0.63) | DDB1CRBNGPR119ALDH1A1 | |
| SCHEMBL24125836 | 0.89 | DDB1 (0.69) | DDB1CRBNGPR119ALDH1A1 | |
| SCHEMBL29199173 | 0.89 | DDB1 (0.64) | DDB1CRBNGPR119ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250084081-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2025-03-13 | — | — | US | disclosed |
| US-12157735-B2 | Compounds for targeted degradation of BRD9 | C4 THERAPEUTICS, INC. (US) | 2024-12-03 | — | — | US | disclosed |
| US-12049464-B2 | Compounds for targeted degradation of BRD9 | C4 THERAPEUTICS, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| US-20240051953-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2024-02-15 | — | — | US | disclosed |
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20230060334-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | US | disclosed |
| EP-4114392-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 Therapeutics, Inc. (US) | 2023-01-11 | — | — | EP | disclosed |
| US-20220098194-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 THERAPEUTICS, INC. (US) | 2022-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230060334-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | BRD9, BRD1, BRWD1 | DDB1 323/4885CRBN 42/4885GPR119 2909/4885 |
| US-20220098194-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | BRD9, BRD1, BRWD1 | DDB1 323/4885CRBN 42/4885GPR119 2909/4885 |
| US-12157735-B2 | Compounds for targeted degradation of BRD9 | BRD9, BRD1, BRWD1 | DDB1 323/4885CRBN 42/4885GPR119 2909/4885 |
| US-12049464-B2 | Compounds for targeted degradation of BRD9 | BRD9, BRD1, BRWD1 | DDB1 323/4885CRBN 42/4885GPR119 2909/4885 |
| US-20240051953-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | BRD9, BRD1, BRWD1 | DDB1 323/4885CRBN 42/4885GPR119 2909/4885 |
| US-20250084081-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | BRD9, BRD1, BRWD1 | DDB1 323/4885CRBN 42/4885GPR119 2909/4885 |
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | BRD9, BRD1, BRWD1 | DDB1 390/4885CRBN 188/4885GPR119 3145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.